{"id":44925,"date":"2022-06-09T22:01:32","date_gmt":"2022-06-09T20:01:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/"},"modified":"2022-06-09T22:01:32","modified_gmt":"2022-06-09T20:01:32","slug":"with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/","title":{"rendered":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots"},"content":{"rendered":"
\n

\nArmed with the world\u2019s largest virus-bacteria interactome repository, Phase Genomics to engineer a predictive engine for the development of new therapies against drug-resistant biothreats<\/i>\n<\/p>\n

SEATTLE–(BUSINESS WIRE)–#metagenomics<\/a>—Phase Genomics, Inc.<\/a>, a leading developer of proximity ligation-based genomic solutions, today announced $5.5MM in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases (NIAID). With the new funding, Phase Genomics will leverage its world\u2019s largest phage-bacteria interactome repository to power the development of a unique AI-driven predictive engine for therapeutic phage discovery.\n<\/p>\n

<\/a><\/p>\n

\nPhages are viruses that prey on bacteria and a promising tool in humanity\u2019s battle against antibiotic resistant infections. Despite being the most abundant form of life on earth, few interactions between phages and their targets are currently documented. Phase Genomics\u2019 proprietary technology captures virus-host interactions directly within microbial communities, without the need for culturing, allowing for rapid discovery of hundreds of new phages and their targets from even single samples.\n<\/p>\n

\nThe new financing, which includes a $3.5MM grant from the Gates Foundation and a $2MM SBIR award from NIAID, will allow Phase Genomics to harness its proximity-guided metagenomics platform, ProxiMetaTM<\/sup>, to develop the world\u2019s largest atlas of phage-bacteria interactions and use machine learning tools to identify phages that can be used in therapeutic settings such as C. difficile<\/i> infections, Ulcerative colitis, and Crohn\u2019s disease. This technology will also empower improved monitoring of wastewater for resistant pathogens.\n<\/p>\n

\n\u201cWe are truly at the frontier of a new understanding of how to improve the human condition,\u201d said Ivan Liachko, PhD, founder and CEO of Phase Genomics. \u201cThe potential to leverage the knowledge of how viruses and bacteria interact is immense. Combined efforts with our strategic partners will help develop a global biodefense shield for pandemic prevention. We plan for the new phage atlas to serve as a resource to help combat pathogen outbreaks and other biological threats, including drug resistance caused by the overuse of antibiotics.\u201d\n<\/p>\n

\nAntimicrobial resistant (AMR) infection is a leading cause of intractable disease. Global health experts project that it will add $1.2 trillion to yearly global health expenditures and surpass cancer as a leading cause of death by 2050.\n<\/p>\n

\nBroad visibility into global microbial populations enables prediction of potential sources of AMR outbreaks before they occur. It can also predict the severity of epidemics, as well as aid in the development of protective measures, like phage-based therapies. Phase Genomics will use the funding to extend its AMR atlas\u2019 reach through international sample collection at scale to monitor the proliferation of mobile genetic elements bearing resistance traits in disparate bacterial communities.\n<\/p>\n

\n\u201cPhage therapeutics are a promising avenue to overcoming the looming public AMR health crisis, but our limited understanding of virus-microbe interaction and bacterial host range is a significant barrier to the advancement of this technology,\u201d said Chris Mason<\/a>, PhD, professor and renowned geneticist. \u201cBy combining machine learning tools with a vast repository of phage interactome data we\u2019ll finally shed light on a vast scientific blind spot that will help advance global public health and help mitigate against the catastrophe of future pandemics.\u201d\n<\/p>\n

\nA recent study published in Nature Biotechnology<\/a> demonstrates the power of Phase Genomics\u2019 unique technology. Researchers, using Phase Genomics\u2019 ProxiMetaTM<\/sup> metagenome deconvolution platform, were able to describe lineage-resolved microbial communities, aligning mobile genetic elements with host genomes and identifying hundreds of novel phage-host associations in a single microbiome sample.\n<\/p>\n

\nFollow Phase Genomics on Twitter<\/a> and LinkedIn<\/a> for the latest news and information.\n<\/p>\n

\nABOUT PHASE GENOMICS<\/b>\n<\/p>\n

\nPhase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, they also offer an industry-leading genome and metagenome assembly and analysis software.\n<\/p>\n

\nBased in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company\u2019s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEric Schudiske
\n
eric@s2spr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Armed with the world\u2019s largest virus-bacteria interactome repository, Phase Genomics to engineer a predictive engine for the development of new therapies against drug-resistant biothreats SEATTLE–(BUSINESS WIRE)–#metagenomics—Phase Genomics, Inc., a leading developer of proximity ligation-based genomic solutions, today announced $5.5MM in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44925","6":"format-standard","7":"category-industry"},"yoast_head":"\nWith New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Armed with the world\u2019s largest virus-bacteria interactome repository, Phase Genomics to engineer a predictive engine for the development of new therapies against drug-resistant biothreats SEATTLE–(BUSINESS WIRE)–#metagenomics—Phase Genomics, Inc., a leading developer of proximity ligation-based genomic solutions, today announced $5.5MM in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-09T20:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots\",\"datePublished\":\"2022-06-09T20:01:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/\"},\"wordCount\":699,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609005985\\\/en\\\/1482492\\\/21\\\/Phase_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/\",\"name\":\"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609005985\\\/en\\\/1482492\\\/21\\\/Phase_Logo.jpg\",\"datePublished\":\"2022-06-09T20:01:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609005985\\\/en\\\/1482492\\\/21\\\/Phase_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609005985\\\/en\\\/1482492\\\/21\\\/Phase_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/","og_locale":"en_US","og_type":"article","og_title":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend","og_description":"Armed with the world\u2019s largest virus-bacteria interactome repository, Phase Genomics to engineer a predictive engine for the development of new therapies against drug-resistant biothreats SEATTLE–(BUSINESS WIRE)–#metagenomics—Phase Genomics, Inc., a leading developer of proximity ligation-based genomic solutions, today announced $5.5MM in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-09T20:01:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots","datePublished":"2022-06-09T20:01:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/"},"wordCount":699,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/","url":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/","name":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg","datePublished":"2022-06-09T20:01:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220609005985\/en\/1482492\/21\/Phase_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/with-new-funding-phase-genomics-seeks-to-eliminate-one-of-biologys-biggest-blind-spots\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44925"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44925\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}